- Available
NCT05238311: Pre-approval Single-patient Expanded Access for Elranatamab (PF-06863135)
NCT05238311: Pre-approval Single-patient Expanded Access for Elranatamab (PF-06863135)
Pre-approval Single-patient Expanded Access for Elranatamab (PF-06863135)
Provide pre-approval single-patient Expanded Access (Compassionate Use) of elranatamab for patients with relapsed/refractory multiple myeloma
Sponsor
Collaborator
In Expanded Access, treating physicians are the Sponsors
ClinicalTrials.gov Identifier: NCT05238311
NCT05238311: Pre-approval Single-patient Expanded Access for Elranatamab (PF-06863135)
First Posted : February 14, 2022
Click here for details on Clinicaltrials.gov
You don’t have to take on multiple myeloma alone | Pfizer Clinical Trials
Elranatamab (Code C146860)
Anti-CD3/Anti-BCMA Bispecific Antibody PF-06863135
B-cell Maturation Antigen-CD3 Bispecific Antibody PF-06863135
BCMA x CD3 Bispecific Antibody PF-06863135
BCMA-CD3 Bispecific Ab PF-06863135
Elranatamab
ELRANATAMAB
PF 06863135
PF-06863135
PF06863135
RN 613
RN-613
RN613
Drug: Elranatamab (PF-06863135)
RELATED POSTS
MagnetisMM-1
NCT03269136: Phase 1 -PF-06863135 As Single Agent & with Immunomodulatory Agents In relapsed Myeloma - MagnetisMM-1
MAGNETISMM-2
NCT04798586: Phase 1: Study of Elranatamab (PF-06863135) in Japanese Patients Myeloma - MAGNETISMM-2
MagnetisMM-3
NCT04649359: Phase 2: Elranatamab (PF-06863135) Monotherapy in relapsed Myeloma - MagnetisMM-3
MagnetisMM-4
NCT05090566: Phase 2: Umbrella Study of Elranatamab (PF-06863135) + Anti-Cancer Tx RRMM - MagnetisMM-4
MagnetisMM-5
NCT05020236: Phase 3: Elranatamab (PF-06863135) Vs & Elranatamab/Dara VS Dara/Pom/Dex - MagnetisMM-5
MagnetisMM-7
NCT05317416: Phase 3: Elranatamab Versus Lenalidomide in Patients With NDMM post ASCT - MagnetisMM-7
MagnetisMM-8
NCT05228470: Phase 2: Study Of Elranatamab (PF-06863135) Monotherapy in China RRMM - MagnetisMM-8
MagnetisMM-9
NCT05014412: Phase 1/2: Elranatamab in MM That Has Come Back or Has not responded - MagnetisMM-9